Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD) (DUAL™ II China)

18 mars 2020 mis à jour par: Novo Nordisk A/S

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other OAD

This trial is conducted in Asia. The aim of this trial is to confirm the superiority of insulin degludec/liraglutide versus insulin degludec in controlling glycaemia in Chinese subjects with type 2 diabetes mellitus after 26 weeks of treatment

Aperçu de l'étude

Statut

Complété

Les conditions

Intervention / Traitement

Type d'étude

Interventionnel

Inscription (Réel)

453

Phase

  • Phase 3

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

  • Chine
    • Anhui
      • Hefei, Anhui, Chine, 230001
        • Novo Nordisk Investigational Site
      • Hefei, Anhui, Chine, 230061
        • Novo Nordisk Investigational Site
    • Beijing
      • Beijing, Beijing, Chine, 100730
        • Novo Nordisk Investigational Site
      • Beijing, Beijing, Chine, 100071
        • Novo Nordisk Investigational Site
      • Beijing, Beijing, Chine, 100088
        • Novo Nordisk Investigational Site
      • Beijing, Beijing, Chine, 100853
        • Novo Nordisk Investigational Site
    • Chongqing
      • ChongQing, Chongqing, Chine, 404000
        • Novo Nordisk Investigational Site
    • Fujian
      • Fuzhou, Fujian, Chine, 350001
        • Novo Nordisk Investigational Site
    • Guangdong
      • Guangzhou, Guangdong, Chine, 510120
        • Novo Nordisk Investigational Site
      • Guangzhou, Guangdong, Chine, 510515
        • Novo Nordisk Investigational Site
    • Hebei
      • Hengshui, Hebei, Chine, 053000
        • Novo Nordisk Investigational Site
      • Shijiazhuang, Hebei, Chine, 050000
        • Novo Nordisk Investigational Site
      • Tangshan, Hebei, Chine, 063000
        • Novo Nordisk Investigational Site
    • Heilongjiang
      • Harbin, Heilongjiang, Chine, 150001
        • Novo Nordisk Investigational Site
    • Hunan
      • Yueyang, Hunan, Chine, 414000
        • Novo Nordisk Investigational Site
    • Inner Mongolia
      • Huhehaote, Inner Mongolia, Chine, 010020
        • Novo Nordisk Investigational Site
      • Huhhot, Inner Mongolia, Chine, 010050
        • Novo Nordisk Investigational Site
    • Jiangsu
      • Changzhou, Jiangsu, Chine, 213003
        • Novo Nordisk Investigational Site
      • Nanjing, Jiangsu, Chine, 210011
        • Novo Nordisk Investigational Site
      • Nanjing, Jiangsu, Chine, 210012
        • Novo Nordisk Investigational Site
      • Nanjing, Jiangsu, Chine, 210029
        • Novo Nordisk Investigational Site
      • Zhenjiang, Jiangsu, Chine, 212001
        • Novo Nordisk Investigational Site
    • Jiangxi
      • Nanchang, Jiangxi, Chine, 330006
        • Novo Nordisk Investigational Site
    • Jilin
      • Changchun, Jilin, Chine, 130021
        • Novo Nordisk Investigational Site
      • Changchun, Jilin, Chine, 130033
        • Novo Nordisk Investigational Site
      • Siping, Jilin, Chine, 136000
        • Novo Nordisk Investigational Site
    • Liaoning
      • Dalian, Liaoning, Chine, 116011
        • Novo Nordisk Investigational Site
    • Ningxia
      • Yinchuan, Ningxia, Chine, 750004
        • Novo Nordisk Investigational Site
    • Shaanxi
      • Xi'an, Shaanxi, Chine, 710061
        • Novo Nordisk Investigational Site
    • Shanghai
      • Shanghai, Shanghai, Chine, 200240
        • Novo Nordisk Investigational Site
      • Shanghai, Shanghai, Chine, 200040
        • Novo Nordisk Investigational Site
      • Shanghai, Shanghai, Chine, 200072
        • Novo Nordisk Investigational Site
      • Shanghai, Shanghai, Chine, 201199
        • Novo Nordisk Investigational Site
    • Shanxi
      • Taiyuan, Shanxi, Chine, 030001
        • Novo Nordisk Investigational Site
    • Tianjin
      • Tianjin, Tianjin, Chine, 300052
        • Novo Nordisk Investigational Site
    • Yunnan
      • Kunming, Yunnan, Chine, 650101
        • Novo Nordisk Investigational Site
  • Hong Kong
      • Shatin, New Territories, Hong Kong
        • Novo Nordisk Investigational Site

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria: Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including procedures to determine suitability for the trial - Male or female, age at least 18 years at the time of signing inform consent - Type 2 diabetes mellitus (clinically diagnosed) - HbA1c (glycosylated haemoglobin) above or equal to 7.5% by central laboratory analysis, with the aim of a median of 8.5%. When approximately 50% of the randomised subjects have an HbA1c above 8.5%, the remaining subjects randomised must have an HbA1c below or equal to 8.5% or when approximately 50% of the subjects randomised have an HbA1c below or equal to 8.5%, the remaining subjects randomised must have an HbA1c above 8.5% - Current treatment for at least 90 calendar days prior to screening with basal insulin plus metformin plus/minus α-glucosidase inhibitors, sulphonylureas, glinides or thiazolidinediones. Subjects should be on a stable dose for at least 60 calendar days prior to screening of: Basal insulin 20-50 units (U)/day (both inclusive) ( Individual fluctuations of plus/minus 5U during the 60 day period prior to the day of screening are acceptable.) on the day of screening in combination with: - Metformin (above or equal to 1500 mg or max tolerated dose) or - Metformin (above or equal to 1500 mg or max tolerated dose) and sulphonylureas (above or equal to half of the max approved dose according to local label) or - Metformin (above or equal to 1500 mg or max tolerated dose) and glinide (at least half of the max approved dose according to local label) or - Metformin (above or equal to 1500 mg or max tolerated dose) and α-glucosidase inhibitors (AGI) (at least half of the max approved dose according to local label) or - Metformin (above or equal to 1500 mg or max tolerated dose) and thiazolidinediones (at least half of the max approved dose according to local label) - Body mass index (BMI) above or equal to 24 kg/m^2 Exclusion Criteria: Current use of any antidiabetic drug (except for basal insulin, metformin, α-glucosidase inhibitors, sulphonylureas, glinides or thiazolidinediones) or anticipated change in concomitant medication, that in the investigator´s opinion could interfere with glucose level (e.g. systemic corticosteroids) - Treatment with glucagon like peptide -1 receptor agonists, or dipeptidyl-peptidase-4 inhibitors or insulin (except for basal insulin) within 90 days prior to Visit 1 - Impaired liver function defined as alanine aminotransferase above or equal to 2.5 times upper normal range - Impaired renal function defined as serum-creatinine above or equal to 133 μmol/L for males and above or equal to 125 μmol/L for females, or as defined according to local contraindications for metformin Screening calcitonin above or equal to 50 ng/L - Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2) - Cardiac disorder defined as: congestive heart failure (NYHA class III-IV), diagnosis of unstable angina pectoris, cerebral stroke and/or myocardial infarction within the last 12 months prior to screening and/or planned coronary, carotid or peripheral artery revascularisation procedures - Severe uncontrolled treated or untreated hypertension (systolic blood pressure above or equal to 180 mm Hg or diastolic blood pressure above or equal to 100 mm Hg) - Proliferative retinopathy or maculopathy (macular oedema) requiring acute treatment - History of pancreatitis (acute or chronic)

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Double

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Insuline dégludec/liraglutide
Médicament: Insulin degludec/liraglutide
Administered subcutaneously (s.c., under the skin) once daily in combination with metformin for the treatment duration of 26 weeks.
Comparateur actif: Insuline dégludec
Médicament: Insulin degludec
Administered subcutaneously (s.c., under the skin) once daily in combination with metformin for the treatment duration of 26 weeks.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Change in HbA1c
Délai: Week 0, week 26
Change in glycosylated haemoglobin (HbA1c) from baseline (week 0) to week 26 is presented.
Week 0, week 26

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Change in Body Weight
Délai: Week 0, week 26
Change in body weight from baseline (week 0) to week 26 is presented.
Week 0, week 26
Number of Treatment-emergent Severe or Blood Glucose (BG) Confirmed Hypoglycaemic Episodes
Délai: Up to 26 weeks
Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the American Diabetes Association (ADA) classification (requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value < 3.1 millimoles per liter (mmol/L) with or without symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Number of treatment-emergent severe or BG confirmed hypoglycaemic episodes during 26 weeks of treatment is presented.
Up to 26 weeks
Change in Fasting Plasma Glucose (FPG)
Délai: Week 0, week 26
Change in FPG from baseline (week 0) to week 26 is presented.
Week 0, week 26
Change in Waist Circumference
Délai: Week 0, week 26
Change in waist circumference from baseline (week 0) to week 26 is presented.
Week 0, week 26
Change in Mean of the 9-point Self-measured Plasma Glucose (SMPG) Profile
Délai: Week 0, week 26
Participants measured plasma glucose values using the blood glucose meter at 9 time points: before breakfast, 90 min after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 min after start of dinner, bedtime, at 4:00 am and before breakfast the following day. The mean of profile is defined as the area under the profile divided by measurement time and is calculated using the trapezoidal method. Change in mean of the 9-point SMPG profile from baseline (week 0) to week 26 is presented.
Week 0, week 26
Change in SMPG-mean Post Prandial Increments
Délai: Week 0, week 26
Participants measured plasma glucose values using the blood glucose meter at 9 time points: before breakfast, 90 min after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 min after start of dinner, bedtime, at 4:00 am and before breakfast the following day. Change in SMPG-mean postprandial increment over all meals from baseline (week 0) to week 26 is presented.
Week 0, week 26
Insulin Dose
Délai: Week 26
The mean of actual daily total insulin dose after 26 weeks of treatment is presented.
Week 26
SMPG-9-point Profile (Individual Points in the Profile)
Délai: Week 26
Participants measured plasma glucose values using the blood glucose meter at 9 time points: before breakfast, 90 min after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 min after start of dinner, bedtime, at 4:00 am and before breakfast the following day. SMPG-9-point profile (individual points in the profile) at week 26 is presented.
Week 26
Change in Fasting High-density Lipoprotein (HDL) Cholesterol- Ratio to Baseline
Délai: Week 0, week 26
Change in fasting HDL cholesterol (measured in mmol/L) from baseline (week 0) to week 26 is presented as ratio to baseline.
Week 0, week 26
Change in Fasting Low-density Lipoprotein (LDL) Cholesterol- Ratio to Baseline
Délai: Week 0, week 26
Change in fasting LDL cholesterol (measured in mmol/L) from baseline (week 0) to week 26 is presented as ratio to baseline.
Week 0, week 26
Change in Fasting Very Low-density Lipoprotein (VLDL) Cholesterol- Ratio to Baseline
Délai: Week 0, week 26
Change in fasting VLDL cholesterol (measured in mmol/L) from baseline (week 0) to week 26 is presented as ratio to baseline.
Week 0, week 26
Change in Fasting Total Cholesterol- Ratio to Baseline
Délai: Week 0, week 26
Change in fasting total cholesterol (measured in mmol/L) from baseline (week 0) to week 26 is presented as ratio to baseline.
Week 0, week 26
Change in Fasting Triglycerides- Ratio to Baseline
Délai: Week 0, week 26
Change in fasting triglycerides (measured in mmol/L) from baseline (week 0) to week 26 is presented as ratio to baseline.
Week 0, week 26
Change in Fasting Free Fatty Acids- Ratio to Baseline
Délai: Week 0, week 26
Change in fasting free fatty acids (measured in mmol/L) from baseline (week 0) to week 26 is presented as ratio to baseline.
Week 0, week 26
Change in Fasting C-peptide- Ratio to Baseline
Délai: Week 0, week 26
Change in fasting C-peptide (measured in nanomoles per liter (nmol/L)) from baseline (week 0) to week 26 is presented as ratio to baseline.
Week 0, week 26
Change in Fasting Insulin- Ratio to Baseline
Délai: Week 0, week 26
Change in fasting insulin (measured in picomoles per liter (pmol/L)) from baseline (week 0) to week 26 is presented as ratio to baseline.
Week 0, week 26
Change in Fasting Glucagon- Ratio to Baseline
Délai: Week 0, week 26
Change in fasting glucagon (measured in picograms per milliliter (pg/mL)) from baseline (week 0) to week 26 is presented as ratio to baseline.
Week 0, week 26
Change in HOMA-B (Beta-cell Function)- Ratio to Baseline
Délai: Week 0, week 26
Change in HOMA-B from baseline (week 0) to week 26 is presented as ratio to baseline.
Week 0, week 26
Participants Who Achieved HbA1c < 7.0%, ADA Target (Yes/no)
Délai: Week 26
Participants who achieved HbA1c < 7.0%, ADA target (yes/no) is presented.
Week 26
Participants Who Achieved HbA1c ≤ 6.5%, American Association of Clinical Endocrinologists (AACE) Target (Yes/no)
Délai: Week 26
Participants who achieved HbA1c ≤ 6.5%, AACE target (yes/no) is presented.
Week 26
Participants Who Achieved HbA1c < 7.0% and Change From Baseline in Body Weight Below or Equal to Zero
Délai: Week 26
Participants who achieved HbA1c < 7.0% and change from baseline in body weight below or equal to zero is presented.
Week 26
Participants Who Achieved HbA1c ≤ 6.5% and Change From Baseline in Body Weight Below or Equal to Zero
Délai: Week 26
Participants who achieved HbA1c ≤ 6.5% and change from baseline in body weight below or equal to zero is presented.
Week 26
Participants Who Achieved HbA1c < 7.0% Without Treatment-emergent Severe or BG Confirmed Hypoglycaemic Episodes
Délai: Week 26
Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value < 3.1 mmol/L with or without symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Participants who achieved HbA1c < 7.0% at week 26 without treatment-emergent severe or BG confirmed hypoglycaemic episodes during the last 12 weeks of treatment is presented.
Week 26
Participants Who Achieved HbA1c ≤ 6.5% Without Treatment-emergent Severe or BG Confirmed Hypoglycaemic Episodes
Délai: Week 26
Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value < 3.1 mmol/L with or without symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Participants who achieved HbA1c ≤ 6.5% at week 26 without treatment-emergent severe or BG confirmed hypoglycaemic episodes during the last 12 weeks of treatment is presented.
Week 26
Participants Who Achieved HbA1c < 7.0% and Change From Baseline in Body Weight Below or Equal to Zero and Without Treatment-emergent Severe or BG Confirmed Hypoglycaemic Episodes
Délai: Week 26
Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value < 3.1 mmol/L with or without symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Participants who achieved HbA1c < 7.0% and change from baseline in body weight below or equal to zero and without treatment-emergent severe or BG confirmed hypoglycaemic episodes during the last 12 weeks of treatment is presented.
Week 26
Participants Who Achieved HbA1c ≤ 6.5% and Change From Baseline in Body Weight Below or Equal to Zero and Without Treatment-emergent Severe or BG Confirmed Hypoglycaemic Episodes
Délai: Week 26
Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value < 3.1 mmol/L with or without symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Participants who achieved HbA1c ≤ 6.5% and change from baseline in body weight below or equal to zero and without treatment-emergent severe or BG confirmed hypoglycaemic episodes during the last 12 weeks of treatment is presented.
Week 26
Number of Treatment-emergent Adverse Events (TEAEs)
Délai: Weeks 0-27
A TEAE was defined as an adverse event with onset date on or after the first day of exposure to randomised treatment and no later than seven days after the last day of randomised treatment. If the event had onset date before the first day of exposure on randomised treatment and increased in severity during the treatment period and until 7 days after the last drug date, then this event was considered as a TEAE.
Weeks 0-27
Number of Treatment-emergent Nocturnal Severe or BG Confirmed Hypoglycaemic Episodes
Délai: Weeks 0-27
Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value < 3.1 mmol/L with or without symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Nocturnal hypoglycaemic episodes were episodes occurring between 00:01 and 05.59 a.m. both inclusive. Number of treatment-emergent nocturnal severe or BG confirmed hypoglycaemic episodes is presented.
Weeks 0-27
Number of Treatment-emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes
Délai: Weeks 0-27
Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value < 3.1 mmol/L with symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Number of treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes is presented.
Weeks 0-27
Number of Treatment-emergent Nocturnal Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes
Délai: Weeks 0-27
Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value < 3.1 mmol/L with symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Nocturnal hypoglycaemic episodes were episodes occurring between 00:01 and 05.59 a.m. both inclusive. Number of treatment-emergent nocturnal severe or BG confirmed symptomatic hypoglycaemic episodes is presented.
Weeks 0-27
Number of Treatment-emergent Hypoglycaemic Episodes According to ADA Definition
Délai: Weeks 0-27
Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Number of treatment-emergent hypoglycaemic episodes according to ADA definition is presented.
Weeks 0-27
Change in Physical Examination
Délai: Week -2, week 26
Physical examination parameters are categorised as cardiovascular system; central and peripheral nervous system; gastrointestinal system including mouth; general appearance; head, ears, eyes, nose, throat, neck; lymph node palpation; musculoskeletal system; respiratory system; skin and thyroid gland. The number of participants assessed as normal, abnormal not clinically significant (NCS) and abnormal clinically significant (CS) at week -2 and week 26 is presented.
Week -2, week 26
Eye Examination
Délai: Week -2, week 26
Dilated fundoscopy or fundus photography was performed by the investigator at week -2 and week 26. The results of the examination were interpreted for each eye (left/right) are categorised as normal, abnormal NCS or abnormal CS. Number of participants in each category at week -2 and week 26 were presented.
Week -2, week 26
Change in Electrocardiogram (ECG)
Délai: Week -2, week 26
The ECG was assessed by the investigator at baseline (week -2) and week 26 and categorised as normal, abnormal NCS or abnormal CS. Number of participants in each ECG category at baseline and week 26 were presented.
Week -2, week 26
Change in Pulse
Délai: Week 0, week 26
Change in pulse from baseline (week 0) to week 26 is presented.
Week 0, week 26
Change in Blood Pressure (Systolic and Diastolic Blood Pressure)
Délai: Week 0, week 26
Change in blood pressure (systolic and diastolic blood pressure) from baseline (week 0) to week 26 is presented.
Week 0, week 26
Change in Biochemical Parameter- Amylase, Lipase, Creatinine Kinase, Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP)
Délai: Week 0, week 26
Change in amylase, lipase, creatinine kinase, ALT, AST, ALP from baseline (week 0) to week 26 is presented.
Week 0, week 26
Change in Biochemical Parameter-calcium (Total), Albumin Corrected Calcium, Potassium, Sodium, Urea
Délai: Week 0, week 26
Change in calcium (total), albumin corrected calcium, potassium, sodium, urea from baseline (week 0) to week 26 is presented.
Week 0, week 26
Change in Albumin
Délai: Week 0, week 26
Change in albumin from baseline (week 0) to week 26 is presented.
Week 0, week 26
Change in Total Bilirubin
Délai: Week 0, week 26
Change in total bilirubin from baseline (week 0) to week 26 is presented.
Week 0, week 26
Change in Creatinine
Délai: Week 0, week 26
Change in creatinine from baseline (week 0) to week 26 is presented.
Week 0, week 26
Change in Total Protein
Délai: Week 0, week 26
Change in total protein from baseline (week 0) to week 26 is presented.
Week 0, week 26
Change in Haematological Parameter- Haematocrit
Délai: Week 0, week 26
Change in haematocrit from baseline (week 0) to week 26 is presented.
Week 0, week 26
Change in Haematological Parameter- Haemoglobin
Délai: Week 0, week 26
Change in haemoglobin from baseline (week 0) to week 26 is presented.
Week 0, week 26
Change in Haematological Parameter- Leukocytes and Thrombocytes
Délai: Week 0, week 26
Change in leukocytes and thrombocytes from baseline (week 0) to week 26 is presented.
Week 0, week 26
Change in Haematological Parameter- Erythrocytes
Délai: Week 0, week 26
Change in erythrocytes from baseline (week 0) to week 26 is presented.
Week 0, week 26
Change in Haematological Parameter- Basophils
Délai: Week 0, week 26
Change in basophils from baseline (week 0) to week 26 is presented.
Week 0, week 26
Change in Haematological Parameter- Eosinophils
Délai: Week 0, week 26
Change in eosinophils from baseline (week 0) to week 26 is presented.
Week 0, week 26
Change in Haematological Parameter- Lymphocytes
Délai: Week 0, week 26
Change in lymphocytes from baseline (week 0) to week 26 is presented.
Week 0, week 26
Change in Haematological Parameter- Monocytes
Délai: Week 0, week 26
Change in monocytes from baseline (week 0) to week 26 is presented.
Week 0, week 26
Change in Haematological Parameter- Neutrophils
Délai: Week 0, week 26
Change in neutrophils from baseline (week 0) to week 26 is presented.
Week 0, week 26
Change in Calcitonin
Délai: Week 0, week 26
Calcitonin levels were measured and were categorised as low, normal or high. Number of participants in each category at week 0 and week 26 were presented.
Week 0, week 26
Urinalysis (Erythrocytes, Protein, Glucose and Ketones)
Délai: Week 0, week 26
The urinalysis was the measurements of protein, glucose, erythrocytes and ketones at week 0 and week 26 and categorised as negative, trace, 1+, 2+ and 3+. Number of participants in each category at week 0 and week 26 are presented.
Week 0, week 26
Anti-insulin Degludec Specific Antibodies
Délai: Week 27
Serum samples were analysed for the presence of anti-insulin degludec specific antibodies. Results are presented as percentage of bound radioactivity-labelled insulin/total added radioactivity-labelled insulin (%B/T).
Week 27
Antibodies Cross-reacting to Human Insulin
Délai: Week 27
Serum samples were analysed for the presence of antibodies cross-reacting to human insulin. Results are presented as percentage of bound radioactivity-labelled insulin/total added radioactivity-labelled insulin (%B/T).
Week 27
Total Insulin Antibodies
Délai: Week 27
Serum samples were analysed for the presence of total insulin antibodies. Results are presented as percentage of bound radioactivity-labelled insulin/total added radioactivity-labelled insulin (%B/T).
Week 27
Occurrence of Anti-liraglutide Antibodies (Yes/no)
Délai: Week 27
This outcome measure is only applicable for the Insulin degludec/liraglutide treatment arm. Number of participants who measured with anti-liraglutide antibodies at week 27 are presented.
Week 27
Occurrence of Anti-liraglutide Antibodies Cross Reacting Native Glucagon-like Peptide-1 (GLP-1)
Délai: Week 27
This outcome measure is only applicable for the Insulin degludec/liraglutide treatment arm. Number of participants who measured with anti-liraglutide antibodies cross reacting native GLP-1 at week 27 are presented.
Week 27
Occurrence of Neutralising Liraglutide Antibodies
Délai: Week 27
This outcome measure is only applicable for the Insulin degludec/liraglutide treatment arm. Number of participants who measured with neutralising liraglutide antibodies at week 27 are presented.
Week 27
Occurrence of Neutralising Liraglutide Antibodies Cross Reacting Native GLP-1
Délai: Week 27
This outcome measure is only applicable for the Insulin degludec/liraglutide treatment arm. Number of participants who measured with neutralising liraglutide antibodies cross reacting native GLP-1 at week 27 are presented.
Week 27

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Novo Nordisk A/S

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

26 mai 2017

Achèvement primaire (Réel)

5 mars 2019

Achèvement de l'étude (Réel)

4 avril 2019

Dates d'inscription aux études

Première soumission

24 mai 2017

Première soumission répondant aux critères de contrôle qualité

2 juin 2017

Première publication (Réel)

5 juin 2017

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

19 mars 2020

Dernière mise à jour soumise répondant aux critères de contrôle qualité

18 mars 2020

Dernière vérification

1 mars 2020

Plus d'information

Termes liés à cette étude

Termes MeSH pertinents supplémentaires

Autres numéros d'identification d'étude

  • NN9068-4166
  • U1111-1154-6732 (Autre identifiant: World Health Organization (WHO))
  • CTR20060909 (Identificateur de registre: China Drug Trials (China))

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

Oui

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

produit fabriqué et exporté des États-Unis.

Oui

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

Essais cliniques sur Diabète sucré, Type 2

Essais cliniques sur Insulin degludec/liraglutide

Rechercher des essais similaires

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

CROs by country

CROs in Türkiye

Conditions

Maladies rares

Interventions en matière de drogue

Compléments alimentaires

Commanditaire / collaborateurs

Emplacements

S'abonner